ABSTRACT
Introduction: Sentinel node mapping is a new technique of lymph nodal staging in solid tumors, which can decrease the morbidity of regional lymph node dissection considerably. Intra-thoracic tumors including non-small cell lung cancer [NSCLC] and esophageal carcinoma [EC] are among the solid tumors in which sentinel node [SN] mapping has been applied. In the current systematic review, we gathered the best available evidence [systematic reviews] in this regard and presented the results in a systematic review format
Material and methods: We searched MEDLINE and SCOPUS since the inception till 13 December 2014 using the following keywords: [lung OR esophagus OR esophageal] AND sentinel AND [systematic review OR meta-analysis OR metaanalysis]. No language limit was imposed on the search strategy. Systematic reviews and meta-analyses on SN mapping in EC or NSCLC were included in the current study. Narrative review articles were excluded from the study
Results: Overall five systematic review were included. One of the included studies was on SN mapping in NSCLC and four were on EC. Overall detection rate and sensitivity for EC and NSCLC were high and both were related to mapping technique, pathological involvement of the mediastinal nodes, size and location of the tumors
Conclusion: SN mapping is feasible and highly accurate in EC and NSCLC. Attention to the technique [using radiotracers, peri-tumoral injection] and restriction of the patients to less advanced cases [cN0 and T1, 2] would ensure the best results with high detection rate and sensitivity
ABSTRACT
Radioimmunotherapy [RIT] is a very promising new therapy for the treatment of recurrent B-Cell non-Hodgkin's lymphoma [NHL]. Iodine-131 is the most frequently used nuclide in clinical RIT, but its usefulness has been limited by dehalogenation of monoclonal antibodies labeled via conventional methods. To circumvent this problem, we have synthesized a tri-peptide consisting of non-metabolizable D amino acids attached to N-Hydroxysuccinimide [NHS]. Tri-peptide was synthesized by standard Fmoc solid phase synthesis on tritylchloride resin. Labeling of tri-peptide was performed using the chloramine-T method and the conventional extraction. Radioiodination of tri-peptide was followed by conjugation to anti-CD20 antibody. In vitro stability of labeled antibody in serum and phosphate buffered saline [PBS] was measured for 48hr by [thin layer chromatography] TLC. Raji cell line was used to test cell binding of the labeled anti-CD20. The chemical purity of synthesized peptide as assessed by analytical [high performance liquid chromatography] HPLC was 95%. Labeling of tri-peptide resulted in a radiochemical yield of 50-71% with radiochemical purity of > 95%. At Rituximab concentration of 10mg/ml, coupling efficiencies of 65-80% was obtained with radiochemical purity of 95% and Specific activity [SA] of 185MBq/mg [5mCi/mg]. This study showed that labeling monoclonal antibodies with radioiodine by non-metabolizable D amino acids will improve bio-stability of the product